Skip to Main Content

Good morning. Elizabeth Cooney reporting from STAT’s worldwide headquarters in Boston today, with contributions from Ed Silverman before he takes a break from the news in favor of a cultural excursion. Happy to receive any tips you might have.

Public Citizen filed a petition urging the Food and Drug Administration to immediately require stronger warnings about an increased risk of spinal fractures when patients stop taking the Prolia osteoporosis drug sold by Amgen (AMGN). The advocacy group cited a “growing body of evidence” showing patients who stop using the drug have an increased risk of multiple vertebral fractures in the spine as soon as seven months after their last dose. Such fractures can cause severe, disabling pain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED